




- (51) **International Patent Classification:**
C07D 487/04 (2006.01) *C07D 519/00* (2006.01)
- (21) **International Application Number:**
PCT/IB2013/055039
- (22) **International Filing Date:**
19 June 2013 (19.06.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/666,299 29 June 2012 (29.06.2012) US
61/820,828 8 May 2013 (08.05.2013) US
- (71) **Applicant:** PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US).
- (72) **Inventors:** GALATSIS, Paul; 375 Cherry Street, Newton, MA 02465 (US). HAYWARD, Matthew Merrill; 3 Pyrus Court, Old Lyme, Connecticut 06371 (US). HENDERSON, Jaclyn; 36 Highland Avenue, Apt. 54, Cambridge, Massachusetts 02139 (US). KORMOS, Bethany Lyn; 46 Quincy Street, #3, Somerville, Massachusetts 02143 (US). KURUMBAIL, Ravi G; 4 Harvest Glen, East Lyme, Connecticut 06333 (US). STEPAN, Antonia Friederike; 50 Park Row West, Apt. 420, Providence, Rhode Island 02903 (US). VERHOEST, Patrick Robert; 23 Calvin Road, Newton, Massachusetts 02460 (US). WAGER, Travis T.; 465 Washington Street, Apt. 6, Brookline, Massachusetts 02446 (US). ZHANG, Lei; 75 Bourne Street, Auburndale, Massachusetts 02466 (US).
- (74) **Agent:** OLSON, A. Dean; Pfizer Inc., Eastern Point Road MS8260-2141, Groton, Connecticut 06340 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) **Title:** NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS

(57) **Abstract:** The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3- c]/pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R^1 , R^2 , R^3 , R^4 and R^5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

WO 2014/001973 A1



Published:

— *with international search report (Art. 21(3))*